AvidBiotics Receives Two New Grants for Narrow-Spectrum Antibacterial Proteins, Bringing Total National Institutes of Health (NIH) Funding to Date to $4 Million

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--AvidBiotics today announced the receipt of two new grants totaling $1 million dollars from the National Institutes of Health that further the development of the company’s novel Avidocin™ platform for narrow spectrum antibacterial proteins against important health care threats. These grants add to three previous grants covering AvidBiotics’ anti-infectious disease technologies, which provide approximately $3.4 million in currently active funding for the company.